Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 2
1992 3
1993 5
1994 3
1995 6
1996 5
1997 1
1998 10
1999 4
2000 8
2001 4
2002 4
2003 4
2004 3
2005 3
2006 4
2007 3
2008 7
2009 5
2010 8
2011 12
2012 12
2013 18
2014 12
2015 20
2016 25
2017 25
2018 31
2019 34
2020 45
2021 26
2022 32
2023 28
2024 28
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

378 results

Results by year

Filters applied: . Clear all
Page 1
Multiple sclerosis.
Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA. Filippi M, et al. Among authors: piehl f. Nat Rev Dis Primers. 2018 Nov 8;4(1):43. doi: 10.1038/s41572-018-0041-4. Nat Rev Dis Primers. 2018. PMID: 30410033 Review.
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Neurofilaments as biomarkers in neurological disorders.
Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J. Khalil M, et al. Among authors: piehl f. Nat Rev Neurol. 2018 Oct;14(10):577-589. doi: 10.1038/s41582-018-0058-z. Nat Rev Neurol. 2018. PMID: 30171200 Review.
Neurofilaments as biomarkers in neurological disorders - towards clinical application.
Khalil M, Teunissen CE, Lehmann S, Otto M, Piehl F, Ziemssen T, Bittner S, Sormani MP, Gattringer T, Abu-Rumeileh S, Thebault S, Abdelhak A, Green A, Benkert P, Kappos L, Comabella M, Tumani H, Freedman MS, Petzold A, Blennow K, Zetterberg H, Leppert D, Kuhle J. Khalil M, et al. Among authors: piehl f. Nat Rev Neurol. 2024 May;20(5):269-287. doi: 10.1038/s41582-024-00955-x. Epub 2024 Apr 12. Nat Rev Neurol. 2024. PMID: 38609644 Review.
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group. Howard JF Jr, et al. Among authors: piehl f. Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22. Neurology. 2019. PMID: 31118245 Free PMC article. Clinical Trial.
Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial.
Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA, Håkansson I, Johansson R, Jons D, Kmezic I, Lindberg C, Lindh J, Lundin F, Nygren I, Punga AR, Press R, Samuelsson K, Sundström P, Wickberg O, Brauner S, Frisell T. Piehl F, et al. JAMA Neurol. 2022 Nov 1;79(11):1105-1112. doi: 10.1001/jamaneurol.2022.2887. JAMA Neurol. 2022. PMID: 36121672 Free PMC article.
Multiple Sclerosis, Disease-Modifying Therapies, and Infections.
Langer-Gould AM, Smith JB, Gonzales EG, Piehl F, Li BH. Langer-Gould AM, et al. Among authors: piehl f. Neurol Neuroimmunol Neuroinflamm. 2023 Oct 9;10(6):e200164. doi: 10.1212/NXI.0000000000200164. Print 2023 Nov. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37813594 Free PMC article.
378 results